Figure 2
EFS and OS by intention-to-treat analysis in 421 patients with AL amyloidosis treated with HDM/SCT. Median EFS, 2.6 years (95% CI, 2.0-3.4 years); median OS, 6.3 years (95% CI, 5.4-7.4 years).
EFS and OS by intention-to-treat analysis in 421 patients with AL amyloidosis treated with HDM/SCT. Median EFS, 2.6 years (95% CI, 2.0-3.4 years); median OS, 6.3 years (95% CI, 5.4-7.4 years).
